Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Stallmach

Showing results (171-180 of 191) with videos related to

Pageof 20
Sort By:
European Archives of Psychiatry and Clinical Neuroscience|August 16, 2023
Longterm course of neuropsychological symptoms and ME/CFS after SARS-CoV-2-infection: a prospective registry studyP A Reuken, B Besteher, K Finke, et al.
Zeitschrift Fur Gastroenterologie|August 14, 2023
T Kucharzik, A Dignass, R Atreya, et al.
Zeitschrift Fur Gastroenterologie|May 8, 2024
T Kucharzik, A Dignass, R Atreya, et al.
Gut|October 14, 2004
NOD2 (CARD15) mutations in Crohn's disease are associated with diminished mucosal alpha-defensin expressionJ Wehkamp, J Harder, M Weichenthal, et al.
Alimentary Pharmacology & Therapeutics|November 29, 2016
Consensus report: faecal microbiota transfer - clinical applications and proceduresJ König, A Siebenhaar, C Högenauer, et al.
Alimentary Pharmacology & Therapeutics|September 24, 2017
Treatment of refractory ascites with an automated low-flow ascites pump in patients with cirrhosisG Stirnimann, T Berg, L Spahr, et al.
Zeitschrift Fur Rheumatologie|September 4, 2014
[German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms: 3 Clinical symptoms]U Kiltz, M Rudwaleit, J Sieper, et al.
Alimentary Pharmacology & Therapeutics|January 16, 2025
Early Dynamics of Portal Pressure Gradient After TIPS Insertion Predict MortalityP A Reuken, A Franz, T H Wirtz, et al.
Zeitschrift Fur Rheumatologie|September 4, 2014
[German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms: 5 Initial diagnosis/referral strategy]U Kiltz, M Rudwaleit, J Sieper, et al.
Leukemia|July 28, 2023
The JAK1/2 inhibitor ruxolitinib in patients with COVID-19 triggered hyperinflammation: the RuxCoFlam trialJ Hammersen, S Birndt, K Döhner, et al.
Pageof 20

Showing results (171-180 of 191) with videos related to

Sort By:
Pageof 20
European Archives of Psychiatry and Clinical Neuroscience|August 16, 2023
Longterm course of neuropsychological symptoms and ME/CFS after SARS-CoV-2-infection: a prospective registry studyP A Reuken, B Besteher, K Finke, et al.
Zeitschrift Fur Gastroenterologie|August 14, 2023
T Kucharzik, A Dignass, R Atreya, et al.
Zeitschrift Fur Gastroenterologie|May 8, 2024
T Kucharzik, A Dignass, R Atreya, et al.
Gut|October 14, 2004
NOD2 (CARD15) mutations in Crohn's disease are associated with diminished mucosal alpha-defensin expressionJ Wehkamp, J Harder, M Weichenthal, et al.
Alimentary Pharmacology & Therapeutics|November 29, 2016
Consensus report: faecal microbiota transfer - clinical applications and proceduresJ König, A Siebenhaar, C Högenauer, et al.
Alimentary Pharmacology & Therapeutics|September 24, 2017
Treatment of refractory ascites with an automated low-flow ascites pump in patients with cirrhosisG Stirnimann, T Berg, L Spahr, et al.
Zeitschrift Fur Rheumatologie|September 4, 2014
[German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms: 3 Clinical symptoms]U Kiltz, M Rudwaleit, J Sieper, et al.
Alimentary Pharmacology & Therapeutics|January 16, 2025
Early Dynamics of Portal Pressure Gradient After TIPS Insertion Predict MortalityP A Reuken, A Franz, T H Wirtz, et al.
Zeitschrift Fur Rheumatologie|September 4, 2014
[German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms: 5 Initial diagnosis/referral strategy]U Kiltz, M Rudwaleit, J Sieper, et al.
Leukemia|July 28, 2023
The JAK1/2 inhibitor ruxolitinib in patients with COVID-19 triggered hyperinflammation: the RuxCoFlam trialJ Hammersen, S Birndt, K Döhner, et al.
Pageof 20